2023-10-09 06:16:43
GSK plc :
*GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP
*EXCLUSIVE AGREEMENT WITH ZHIFEI FOR THE CO-PROMOTION OF GSK’S SHINGLES VACCINE, SHINGRIX, IN CHINA FOR AN INITIAL PERIOD OF THREE YEARS
* THIS PARTNERSHIP WILL CONSIDERATELY EXPAND THE AVAILABILITY OF SHINGRIX IN CHINA THROUGH JOINT PROMOTION AMONG HEALTH PROFESSIONALS AND MORE THAN 30,000 VACCINATION POINTS.
*ZHIFEI WILL PURCHASE AGREED VOLUMES FROM SHINGRIX FOR A TOTAL VALUE OF 2.5 BILLION STERLING POUNDS OVER AN INITIAL PERIOD OF THREE YEARS.
* THERE IS POTENTIAL FOR EXPANDING THE PARTNERSHIP IF ALL PARTIES AGREE.
* PARTNERSHIP SUPPORTS AND ACCELERATE GSK’S COMMITMENT TO DOUBLE SHINGRIX GLOBAL SALES TO MORE THAN 4 BILLION POUNDS BY 2026.
* THE PARTNERSHIP SUPPORTS THE POTENTIAL CO-DEVELOPMENT AND COMMERCIALIZATION OF AREXVY IN CHINA.
*ZHIFEI HAS GRANTED CO THE RIGHT OF FIRST REFUSAL TO BE THE EXCLUSIVE PARTNER FOR THE CO-DEVELOPMENT AND COMMERCIALIZATION OF THE RSV VACCINE FOR OLDER ADULTS IN CHINA Source text for Eikon: More information regarding the company:
1696832719
#GSK #announces #exclusive #agreement #Zhifei #October
